MedTrace Logo

Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients

NCT03904628 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-04-14

No results posted yet for this study

Summary

The aim of the study was to explore the dose-limiting toxicity (DLT) and the maximum tolerable dose (MTD) of oral administration of TG02 capsules twice a week for 4 weeks.

Conditions

  • High-grade Gliomas

Interventions

DRUG

TG02 capsules oral administration, BIW in every 28d

TG02 capsules150mg oral administration, BIW in every 28d

DRUG

TG02 capsules oral administration, BIW in every 28d

TG02 capsules 200mg oral administration, BIW in every 28d

DRUG

TG02 capsules oral administration, BIW in every 28d

TG02 capsules 250mg oral administration, BIW in every 28d

Sponsors & Collaborators

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2020-08-01
Completion
2020-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03904628 on ClinicalTrials.gov